Across TCGA pan-cancer cohorts, NIF3L1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NIF3L1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NIF3L1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NIF3L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where NIF3L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.982	0.500	.004	40	view →
PDAC	DFS	Median	All	0.485	0.331	.008	11	view →
HNSC	DFS	Tertile	All	0.761	0.317	.047	4	view →
LUAD	DFS	Tertile	All	1.000	0.682	.014	3	view →
UCEC	DFS	Tertile	II,III,IV	0.727	1.000	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NIF3L1 tumor-vs-normal RNA expression · all NIF3L1 data types